27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- On Saturday, Travere Therapeutics Inc (NASDAQ:TVTX) presented results from the interim analysis of Phase 3 PROTECT study of Filspari (sparsentan) in IgA nephropathy (IgAN) at the World Congress of Nephrology (WCN) 2023 annual meeting, and concurrently published results of the interim analysis in The Lancet.
- IgA nephropathy (IgAN), also called Berger's disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight kidney infections.
- The additional details from the PROTECT interim analysis demonstrated efficacy across several measures, including changes from baseline to week 36 in urine protein-creatinine ratio (UP/C) of -49.8% for Filspari compared to -15.1% for irbesartan.
- Related: Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment.
- Filspari also achieved significant complete (<0.3 g day) and partial (<0.5 proteinuria remission compared to irbesartan (20.8% versus 7.9% 70.3% 44.1%, respectively).< li>
- The PROTECT Study is fully enrolled and is scheduled to continue as planned on a blinded basis to assess the treatment effect on eGFR slope over 110 weeks in the confirmatory endpoint analysis.
- Topline results from the confirmatory endpoint analysis are expected in the fourth quarter of 2023.
- Price Action: TVTX shares closed higher by 1.81% at $22.49 on Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!